TNF-alpha protects human primary articular chondrocytes from nitric oxide-induced apoptosis via nuclear factor-kappaB

Lab Invest. 2002 Dec;82(12):1661-72. doi: 10.1097/01.lab.0000041714.05322.c0.

Abstract

TNF-alpha plays a key role in rheumatoid arthritis, but its effect on chondrocyte survival is still conflicting. In the present study, we tested how TNF-alpha influences chondrocyte survival in response to nitric oxide (NO)-related apoptotic signals, which are abundant during rheumatoid arthritis. Human primary articular chondrocytes or cartilage explants were pretreated with TNF-alpha for 24 hours and then treated with the proapoptotic NO donor sodium-nitro-prusside (SNP) for an additional 24 hours. TNF-alpha pretreatment markedly protected chondrocytes from SNP-induced cell death. Preincubation of chondrocytes with TNF-alpha inhibited both SNP-induced high-molecular weight DNA fragmentation and annexin V-FITC binding. Of interest, TNF-alpha induced persistent nuclear factor-kappaB (NF-kappaB)-DNA binding activity even in the presence of SNP, mirroring apoptosis protection effects. Both the TNF-alpha antiapoptotic effect and NF-kappaB-DNA binding activity were significantly inhibited by NF-kappaB inhibitors, Bay 11-7085, MG-132, and adenovirus-expressing mutated IkappaB-alpha. Phosphatidylinositol-3 kinase inhibitor LY 294002 also markedly inhibited the antiapoptotic effect of TNF-alpha. In primary chondrocytes, TNF-alpha induced expression of the antiapoptotic protein Cox-2, which persisted in the presence of SNP, and a specific Cox-2 inhibitor significantly blocked the TNF-alpha protective effect. We therefore conclude that TNF-alpha-mediated protection of chondrocytes from NO-induced apoptosis acts through NF-kappaB and requires Cox-2 activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviruses, Human / genetics
  • Adult
  • Aged
  • Anti-Infective Agents / pharmacology
  • Apoptosis / drug effects*
  • Cartilage, Articular
  • Cell Survival / drug effects
  • Cells, Cultured
  • Chondrocytes / drug effects*
  • Chondrocytes / pathology
  • Chromones / pharmacology
  • Cyclooxygenase 2
  • Enzyme Inhibitors / pharmacology
  • Flow Cytometry
  • Genetic Vectors
  • Humans
  • Isoenzymes / antagonists & inhibitors
  • Isoenzymes / biosynthesis
  • Leupeptins / pharmacology
  • Membrane Proteins
  • Middle Aged
  • Morpholines / pharmacology
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / metabolism*
  • Nitric Oxide / pharmacology*
  • Nitric Oxide Donors / pharmacology
  • Nitriles
  • Nitroprusside / pharmacology
  • Prostaglandin-Endoperoxide Synthases / biosynthesis
  • Sulfones
  • Tumor Necrosis Factor-alpha / pharmacology*

Substances

  • Anti-Infective Agents
  • BAY 11-7085
  • Chromones
  • Enzyme Inhibitors
  • Isoenzymes
  • Leupeptins
  • Membrane Proteins
  • Morpholines
  • NF-kappa B
  • Nitric Oxide Donors
  • Nitriles
  • Sulfones
  • Tumor Necrosis Factor-alpha
  • Nitroprusside
  • Nitric Oxide
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde